Status:
COMPLETED
Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Chronic Cavitary Pulmonary Aspergillosis
Eligibility:
All Genders
14-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether there itraconazole is effective in the treatment of chronic cavitary pulmonary aspergillosis
Detailed Description
The role of itraconazole is still not clear in the treatment of chronic cavitary pulmonary aspergillosis(CCPA). Some studies have shown a beneficial role of itraconazole in reducing hemoptysis. So the...
Eligibility Criteria
Inclusion
- Clinical symptoms: -presence of chronic pulmonary/systemic symptoms lasting ≥ six weeks.
- Radiological findings:
- Evidence of slowly progressive pulmonary lesions over weeks-months including cavities with surrounding inflammation.
- presence of intracavitary mass with a surrounding crescent of air,and presence of pleural thickening in peripheral lesions.
- Microbiological/Immunological findings: Positive results in the aspergillus precipitin test, demonstration of aspergillus hyphae in sputum or BAL fluid or cultures of BAL/sputum growing aspergillus species.
- The diagnosis of CCPA will be made if
- Patient satisfies at least 1, 2a or 2b and/ or any of the 3rd criteria.
- FNAC from the cavity wall will be considered in atypical cases
Exclusion
- Invasive aspergillosis
- Allergic broncho-pulmonary aspergillosis (ABPA)
- Active tuberculosis or malignancy
- Pregnant females
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01259336
Start Date
July 1 2010
End Date
December 1 2011
Last Update
February 22 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PGIMER
Chandigarh, Punjab, India, 160012